Immunotherapy to battle Cancer

by Health | 08-09-2017 | 624 views

The United States’s Food and Drug Administration (FDA) has approved ‘Kymriah’ for children and young adults to fight an aggressive type of leukemia — B-cell acute lymphoblastic leukemia. Kymriah was developed by Novartis and is a form of immunotherapy which bolsters the immune system through drugs and other therapies. The new therapy turns a patient’s cells into a ‘living drug’ and trains them to recognize and attack the disease causing cells. Most experts claim this as the first step to fighting cancer. Novartis and other companies have been racing to develop gene therapies for the different types of cancers.

Lets socialize : Share via Whatsapp